Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2024-06-25 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Devonian Health Group's third quarter 2024 financial results and business update. It includes specific financial figures such as revenue growth, net loss per share, cash and debt positions, and operational highlights. The document also mentions the engagement of an investor relations firm. The presence of detailed financial data for the quarter ended April 30, 2024, and the nature of the content (financial results, management comments, business highlights) indicate this is a comprehensive quarterly financial report. The document is approximately 9,837 characters long, which is sufficient to contain substantive financial data and analysis, not just a brief announcement or link to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-06-25 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed offering document for structured financial products called "titres sous forme de billets" (notes) issued by Banque Nationale du Canada. It includes detailed terms of the offering, pricing supplements, risk factors, coupon payment details, maturity, and other investment characteristics. It is not a financial report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. It is not a regulatory filing or certification. It is a prospectus or offering document related to capital raising and issuance of securities. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2024-06-25 English
News release - French.pdf
Investor Presentation Classification · 95% confidence The document is a press release announcing Groupe Santé Devonian's participation in a virtual non-deal roadshow organized by Renmark Financial Communications. It describes the event details, including the date, registration link, and the CEO's participation. The content focuses on investor presentation and communication rather than financial results or regulatory filings. There is no financial data, audit information, or voting results. The document is not a transcript but an announcement of an upcoming investor presentation event. Therefore, the most appropriate classification is 'Investor Presentation' (IP). The document length (7429 characters) supports it being a full announcement rather than a brief notice, and the content aligns with investor presentation details.
2024-06-25 English
Interim MD&A - French.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'T3-2024 Rapport de Gestion' and covers the quarter and nine-month period ended April 30, 2024. It provides a detailed overview of the company's activities, financial situation, research and development updates, and operational performance for these periods. It references interim consolidated financial statements and audited annual financial statements, indicating it is a comprehensive management report for a period shorter than a full fiscal year. The content includes substantive financial data and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-06-25 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3-2024 MANAGEMENT REPORT - FOR THE THREE AND NINE-MONTH PERIODS ENDED APRIL 30, 2024' and contains detailed discussion and analysis of the company's financial position, operating results, research and development activities, and business strategy for the specified interim period. It references unaudited interim consolidated financial statements and provides forward-looking statements, company profile, and detailed operational updates. The content aligns with a Management Discussion and Analysis (MD&A) report, which is typically part of an Interim / Quarterly Report filing. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2024
2024-06-25 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains detailed unaudited interim condensed consolidated financial statements for Devonian Health Group Inc. for the three and nine-month periods ended April 30, 2024 and 2023. It includes consolidated statements of financial position, net loss and comprehensive loss, changes in equity, cash flows, and accompanying notes. The document explicitly states it is prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, and is unaudited. The presence of comprehensive financial data for a period shorter than a full fiscal year, including balance sheets, income statements, cash flow statements, and notes, confirms this is an interim or quarterly report rather than an annual report or other filing type. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2024
2024-06-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.